Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/26087
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-04-26T08:56:32Z-
dc.date.available2022-04-26T08:56:32Z-
dc.date.issued2009-03-
dc.identifier.citationSivrioğlu, Y. vd. (2009). "Factors influencing response and remission in the treatment of major depressive disorder: Can social adaptation be a determinant factor?". Klinik Psikofarmakoloji Bülteni, 19(Supplement 1), S137-S139.tr_TR
dc.identifier.issn1017-7833-
dc.identifier.urihttp://hdl.handle.net/11452/26087-
dc.description.abstractObjective: Major depression is a frequent disorder successfully treated with antidepressants (1). Response and remission depend on the type of pharmacological treatment as well as patient characteristics. The aim of the study is to evaluate the factors influencing response and remission rates. Method: Data from 4 studies (2-4) sharing the same methodology is pooled and reanalyzed. Subjects with major depression were assigned to reboxetine, sertraline or venlafaxine XR treatment in an open label fashion. The initial dose of reboxetine and venlafaxine XR were 4mg/day and 75mg/day respectively. The dose was increased at the second week to 8mg/day for reboxetine and 150mg/day for venlafaxine XR. Sertraline dose was 50mg/day throughout the study. Subjects were assessed at baseline, 2 weeks, 4 weeks, 7 weeks and 10 weeks with Hamilton Depression Rating Scale (HDRS) (5), Hamilton Anxiety Rating Scale (HARS) (6) and, Social Adaptation Self-Evaluation Scale (SASS) (7). Results: Characteristics of the study population (n=149) are summarized in Table 1. The response and remission rates were 67.8% (n=101) and 55% (n=82) respectively. Total number of episodes, time since first episode, baseline HDRS and HARS scores were significantly lower and baseline SASS score was significantly higher in responders and remitters when compared to non-responders and non-remitters respectively (Table 2). Logistic regression analyses where response and remission were dependent variables and, treatment arm, gender, age, duration of last episode, number of past episodes,.time since first episode and baseline HDRS, HADRS and SASS scores were independent variables revealed that baseline SASS score was the only factor significantly increasing the odds of response (p=0.035 OR:1.06 %95 CI: 1.005-1.131) and remission (p=0,019 OR:1,07 %95CI: 1,012-1,140). Conclusion: Our findings suggest that baseline social adaptation may have a modest impact on response and remission but other factors not evaluated in our study may also influence the rates of response and remission.en_US
dc.language.isotrtr_TR
dc.publisherKüre İletişimtr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMajor depressionen_US
dc.subjectPharmacotherapyen_US
dc.subjectReboxetineen_US
dc.subjectRemissionen_US
dc.subjectReplyen_US
dc.subjectSertralineen_US
dc.subjectSocial adaptationen_US
dc.subjectVenlafaxineen_US
dc.subjectReboxetineen_US
dc.subjectEfficacyen_US
dc.subjectTolerabilityen_US
dc.subjectVenlafaxineen_US
dc.subjectSertralineen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectPsychiatryen_US
dc.titleFactors influencing response and remission in the treatment of major depressive disorder: Can social adaptation be a determinant factor?en_US
dc.title.alternativeMajör depresif bozukluk tedavisinde yanıt ve remisyona etki eden faktörler: Sosyal uyum belirleyici olabilir mi?tr_TR
dc.typeArticleen_US
dc.identifier.wos000209020900036tr_TR
dc.identifier.scopus2-s2.0-67650763146tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0003-0297-846Xtr_TR
dc.identifier.startpageS137tr_TR
dc.identifier.endpageS139tr_TR
dc.identifier.volume19tr_TR
dc.identifier.issueSupplement 1en_US
dc.relation.journalKlinik Psikofarmakoloji Bültenitr_TR
dc.contributor.buuauthorSivrioğlu, Yusuf-
dc.contributor.buuauthorKırlı, Selçuk-
dc.contributor.buuauthorAkkaya, Cengiz-
dc.contributor.buuauthorEker, Salih Saygın-
dc.contributor.buuauthorÖzkaya, Güven-
dc.contributor.researcheridQ-9477-2019tr_TR
dc.contributor.researcheridA-4421-2016tr_TR
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid14062563200tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid14019347700tr_TR
dc.contributor.scopusid16316866500tr_TR
dc.subject.scopusMorpholines; Reboxetine; Amino Alcoholsen_US
dc.subject.emtreeReboxetineen_US
dc.subject.emtreeSertralineen_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeConference paperen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDrug dose increaseen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeGenderen_US
dc.subject.emtreeGroups by ageen_US
dc.subject.emtreeHamilton Anxiety Scaleen_US
dc.subject.emtreeHamilton scaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLogistic regression analysisen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMajor depressionen_US
dc.subject.emtreeOpen studyen_US
dc.subject.emtreePsychologic assessmenten_US
dc.subject.emtreePsychopharmacotherapyen_US
dc.subject.emtreeRating scaleen_US
dc.subject.emtreeRemissionen_US
dc.subject.emtreeSelf evaluationen_US
dc.subject.emtreeSocial adaptationen_US
dc.subject.emtreeTreatment responseen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.